3,000 Shares in Regeneron Pharmaceuticals, Inc. (REGN) Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,341,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $130,000. Sterling Investment Advisors Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP grew its stake in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares in the last quarter. Alpha Windward LLC grew its stake in shares of Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 67.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/11/13/3000-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-state-of-new-jersey-common-pension-fund-d.html.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 88,942 shares of company stock worth $42,064,076. 10.80% of the stock is owned by insiders.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $404.54 on Monday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The firm has a market capitalization of $43,346.87, a PE ratio of 35.03, a PEG ratio of 1.56 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the previous year, the firm earned $3.13 EPS. The firm’s revenue was up 23.0% compared to the same quarter last year. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.77 earnings per share for the current year.

REGN has been the subject of several recent analyst reports. Bank of America Corporation reiterated a “buy” rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. BMO Capital Markets reaffirmed a “market perform” rating and set a $484.00 price objective (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Barclays PLC reaffirmed an “equal weight” rating and set a $450.00 price objective (up from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price target on the stock. in a research report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $481.49.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply